Accordingly, genetic mouse models of hepatic AMPK deficiency and ACC with knock-in phosphorylation mutations confirmed the importance of the activation of AMPK and phosphorylation of ACC for the improvement of fatty liver disease induced by AMPK-activating drugs [7,8,11]. This evidence concerns the gene PRKAA2 and fatty liver disease.